Table 2.
Multiple logistic regression model for variables associated with CHB in Induction or Consolidation
| Conjugated hyperbilirubinemia | ||
|---|---|---|
| Adjusted OR (95% CI) | P | |
| Age | 1.20 (0.99–1.44) | 0.064 |
| BMI at diagnosis | ||
| <95th Percentile | 1.00 (REF) | 1.00 |
| ≥95th Percentile | 9.20 (2.56–32.96) | 0.001 |
| Ethnicity | ||
| Non-Hispanic | 1.00 (REF) | 1.00 |
| Hispanic | 1.78 (0.43–7.39) | 0.426 |
| Sex | ||
| Male | 1.00 (REF) | 1.00 |
| Female | 1.91 (0.55–6.57) | 0.306 |
| ALL Induction Type | ||
| Three-drug induction1 | 1.00 (REF) | 1.00 |
| Four-drug induction2 | 3.04 (0.26–35.59) | 0.375 |
1
Three-drug induction includes oral dexamethasone, intravenous vincristine, and intramuscular or intravenous pegaspargase
2
Four-drug induction in oral dexamethasone (age <10 years) or prednisone (age ≥10 years), intravenous vincristine, and intramuscular or intravenous pegaspargase, and intravenous daunorubicin